Corus, the leading dental laboratory group in Spain, France and Portugal, and Signadens, reference laboratory group in the Netherlands and Belgium, have joined forces to consolidate the European market of dental laboratories and become the European market leader in digital dental prosthesis.
Both companies unite their forces under the brand name Corus, with the aim of consolidating its position at the forefront of technology and innovation supporting dentists in the ongoing modernization and digital transformation of the industry. As part of its strategy, the company seeks to integrate local entrepreneurs who then become shareholders in the company, maintaining the highest level of service locally to their existing clients. Corus works as an integrated digital platform where dentists can interact with the local laboratory and patient at the same time whilst guaranteeing the traceability of the prescription and information necessary to make the products and services tailored to the patient. This, along with the integration of the wider network of laboratories, offers a global solution based on an innovative and differentiated portfolio of protocols of work, products, services, training and education while maintaining a local and personal environment, thus ensuring a better patient care and experience.
Corus and Signadens reached consolidated €100 million revenue as of the end of 2021. With 49 laboratories and over 1,200 employees they both serve more than 9,000 dental practices spread across Spain, France, Netherlands, Belgium and Portugal. Following the integration, the company plans to grow its revenue to a total of circa €150 million in 2022 by combining organic growth and the consolidation of more laboratories, both in current regions and further afield. In addition, both current private equity investors Careventures and Quadrum Capital have committed to continue their support through the companys plans of future growth.
Corus is led by co-CEOs Jeroen van Asten (Signadens) and Nicolas Bonnard (Corus) who will share responsibilities for the development of the company.
Juan Roma, Partner at Careventures and Executive Chairman of Corus, commented: “At Corus, we are committed to the European development of the company. The confidence, talent and results we have achieved in recent years are testament to the success of our work. Joining forces with Signadens greatly strengthens our position as a leader in the market. Moreover, with the leadership of both Nicolas and Jeroen, I have no doubt that we will continue to achieve success as we see Corus grow further into new markets.”
Nicolas Bonnard, co-CEO, speaks of a new era: “It is a great honour to take on the challenge of leading and developing our company with very talented entrepreneurial partners and an excellent team of experienced managers. Corus, in cooperation with dentists, is driving the paradigm shift in the new era of dentistry: digital, personalised and with high added value for the dentist and for the patient. Based on our corporate structure, where all laboratories own shares in the group, we are well positioned to provide excellent services and products to our customers in the most efficient way.”
Jeroen van Asten, co-CEO said: “The European market for dental prostheses is undergoing a consolidation process. Digitalisation is bringing about far-reaching changes. In the coming years, we want to play a leading role in this transformation by integrating leading laboratories and leveraging the group’s capacity for innovation. We look forward to further expanding our products and services in the European market. Countries such as Germany, the UK or Italy have enormous potential, which we are keen to capitalise on.”
The link to a complete article regarding the interpretation of Corus and Signadens can be found here.